SecBot SecBot
8-K ·Filed Jul 30, 2026

ALNY

ALNYLAM PHARMACEUTICALS, INC.
BEARISH
Impact 7/10
Horizondays Processed3mo ago SEC0001178670-26-000060
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The guidance cut reflects a material deceleration in second-line ATTR-CM demand after initial pent-up launch surge. Traders should monitor upcoming quarterly demand trends and any competitive responses from Pfizer's tafamidis. The raised collaboration/royalty guidance partially offsets but does not change the negative read-through for the core TTR franchise.

DirectionBearish
Confidencehigh
Horizondays

Drugs in focus

ALNY drug pipeline →

brezosiran

● Neutral Named in this 8-K
Impact
Phase
Phase 1b
Time to market
If the pivotal study begins in 2027 as planned, a potential approval would be several years away, likely 2029-2031 assuming positive Phase 3 data and a standard FDA review timeline.
Next catalyst
None dated

What to watchThe next catalyst for brezosiran is the planned initiation of a placebo-controlled pivotal study in 2027, pending regulatory alignment. Positive Phase 1b data (60-64% mean mHTT reduction) supports advancement, but the drug is still early-stage and represents a small part of Alnylam's diversified, approved-product portfolio. Watch for regulatory feedback and trial design details in 2027.

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$205.48
T+0 close · Jul 30, 2026 · via day close
Latest settled
+9.03%
T+60 · $224.03
Vs SPY
+6.56%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 30 $205.48entry
  2. T+1 · 4mo ago +0.02%α −0.69% · $205.52
  3. T+5 · 3mo ago +5.18%α +1.56% · $216.12
  4. T+20 · 3mo ago +15.13%α +11.16% · $236.56
  5. T+60 · 25d ago +9.03%α +6.56% · $224.03
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alnylam reported Q2 2026 non-GAAP diluted EPS of $1.84 (missed consensus of $2.15 by 14.5%) and total revenue of $1.291B (missed $1.32B consensus by 2.2%). The company lowered its full-year 2026 TTR net product revenue guidance from $4.4B-$4.7B to $4.2B-$4.5B, citing normalization of second-line demand after an initial pent-up launch surge. Despite strong 74% YoY product revenue growth, the guidance cut and earnings miss signal a slower-than-expected ATTR-CM launch trajectory.

Key Financial Metrics

EPS
$1.84
est $2.15 · -14.4%
Revenue
$1.3B
est $1.3B · -2.2% · +67.0% YoY
Rating
miss
Guidance
$4.7B-$5.1B (total net product revenues)
lowered
Gross Margin
74.6%

Key Facts

  • Q2 2026 total revenues $1.291B (+67% YoY), net product revenues $1.172B (+74% YoY)
  • GAAP diluted EPS $1.21; non-GAAP diluted EPS $1.84 (missed consensus of $2.15 by 14.5%)
  • Total TTR net product revenues $1.030B (+89% YoY), driven by AMVUTTRA sales of $1.012B (+106% YoY)
  • Full-year 2026 TTR revenue guidance lowered to $4.2B-$4.5B from $4.4B-$4.7B; total product revenue guidance lowered to $4.7B-$5.1B from $4.9B-$5.3B
  • Collaboration and royalty guidance raised to $575M-$625M from $400M-$500M
  • Cash and marketable securities $3.3B as of June 30, 2026

Financial Impact

Full-year 2026 TTR revenue guidance cut by $200M at midpoint ($4.55B to $4.35B); total product revenue guidance cut by $200M at midpoint ($5.1B to $4.9B)

revenueepsguidance

Risk Factors

  • Slower-than-expected ATTR-CM market growth or increased competition
  • Further downward revisions if second-line demand continues to normalize
  • Pipeline setbacks in key programs (zilebesiran, nucresiran, mivelsiran)

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
76% bullish (38 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001178670-26-000060
Document: alny-20260730.htm0001178670-26-000060
Document: 0001178670-26-000060-index-headers.html0001178670-26-000060
Document: 0001178670-26-000060-index.html0001178670-26-000060
Document: 0001178670-26-000060.txt0001178670-26-000060
8-K Data (Synthetic)0001178670-26-000060

Track record

15 reports on ALNY

Performance horizon

1 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +26.35% at T+5 after the Oct 23, 2026 report. 1 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $160.53 Now $159.73 −0.50% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $165.50 Now $159.73 −3.49% settles Nov 23
  3. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $165.04 Now $159.73 −3.22% settles Nov 20
  4. Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $165.04 Now $159.73 −3.22% settles Nov 20
  5. Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $156.66 to $156.65 Now $159.73 +1.96% ▼ −0.01% −3.30% vs SPY
  6. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $156.66 to $156.65 Now $159.73 +1.96% ▼ −0.01% −3.30% vs SPY
  7. Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $165.00 to $155.94 Now $159.73 −3.19% ▼ −5.49% −2.79% vs SPY
  8. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $174.00 to $156.66 Now $159.73 −8.20% ▼ −9.97% −5.24% vs SPY
  9. Oct 23, 202624d ago Institutional Cluster Bearish 4/10 Entry $224.03 to $165.00 Now $159.73 +28.70% ▲ +26.35% +25.79% vs SPY
  10. Aug 17, 202613w ago Court Ruling Neutral 4/10 Entry $228.61 to $240.08 Now $159.73 −30.13% ▲ +5.02% +5.22% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 7h 16m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 30, 2026